Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
XL-184 free base (Cabozantinib)
Cat No.
CEI-0056
Description
As a pan-tyrosine kinase inhibitor, XL-184 (BMS-907351, Cabozantinib) can potently inhibit VEGFR2, Met, Kit, Tie2 and FLT-3 with IC50 of 0.035 nM, 1.8 nM, 4.6 nM, 14.3 nM and 14.4 nM.
Alias
BMS-907351
CAS No.
849217-68-1
Molecular Weight
501.51
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
BMS-907351
Targets
VEGFR2, c-Met, c-Kit, Tie2, FLT-3
Molecular Formula
C28H24FN3O5
Chemical Name
N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Solubility
DMSO 117 mg/mL Water
In vitro
1. Cabozantinib inhibits endothelial cell tubule formation in vitro Cabozantinib inhibited tubule formation with an IC 50 value of 6.7 nmol/L. Cabozantinib also inhibited tubule formation in response to conditioned media derived from cultures of MDA-MB-231 (IC 50 =5.1 nmol/L), A431 (IC 50= 4.1 nmol/L), HT1080 (IC 50 = 7.7 nmol/L), and B16F10 (IC 50 = 4.7 nmol/L) cells. 2. Cabozantinib inhibits cellular migration and invasion Cabozantinib potently inhibited HGF-induced migration (IC 50 = 31 nmol/L) and invasion (IC 50 = 9 nmol/L) of B16F10 cells. VEGF- and HGF-mediated migration of proangiogenic murine MS1 endothelial cells were also sensitive to cabozantinib with IC 50 values of 5.8 and 41 nmol/L.
In vivo
Cabozantinib inhibits MET and VEGFR2 phosphorylation in vivo. A single 100 mg/kg oral dose of cabozantinib resulted in inhibition of phosphorylation of MET 2 to 8 hours postdose in H441 tumors that harbor constitutively phosphorylated MET.
Download
Download Datasheet